ADAPTIMMUNE

adaptimmune-logo

Adaptimmune develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroys cancerous or infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was incorporated in 2007 and is based in Abingdon, United Kingdom.

#SimilarOrganizations #People #Financial #Event #Website #More

ADAPTIMMUNE

Social Links:

Industry:
Biopharma Biotechnology Health Care Medical

Founded:
2008-01-01

Address:
Oxton, York, United Kingdom

Country:
United Kingdom

Website Url:
http://www.adaptimmune.com

Total Employee:
251+

Status:
Active

Contact:
+1 (215) 825 9260

Email Addresses:
[email protected]

Total Funding:
399.5 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Content Delivery Network Google Universal Analytics


Similar Organizations

affimed-logo

Affimed

Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.

agenus-logo

Agenus

Agenus develops and commercializes immunotherapies and vaccines for cancer and infectious diseases.

cel-sci-logo

CEL-SCI

CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.

healx-logo

Healx

Healx is an AI-powered, patient-inspired technology company, pioneering the next generation of drug discovery for rare diseases.

kuros-biosciences-logo

Kuros Biosciences

Kuros Biosurgery develops biomaterials and bioactive biomaterial combination products for indications in trauma, wound and spine.

lineage-cell-therapeutics-logo

Lineage Cell Therapeutics

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cellular therapies to treat unmet medical needs.

soligenix-logo

Soligenix

Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.

theravectys-logo

Theravectys

Theravectys develops a platform for the prevention and treatment of cancers and other infectious diseases and conditions.


Current Advisors List

elliott-sigal_image

Elliott Sigal Board Member @ Adaptimmune
Board_member
2014-09-01

Current Employees Featured

cintia-piccina_image

Cintia Piccina
Cintia Piccina Chief Commercial Officer @ Adaptimmune
Chief Commercial Officer
2022-01-01

not_available_image

Gavin Wood
Gavin Wood Chief Financial Officer @ Adaptimmune
Chief Financial Officer
2020-04-01

not_available_image

William (Bill) Bertrand
William (Bill) Bertrand Chief Operating Officer @ Adaptimmune
Chief Operating Officer

ian-laing_image

Ian Laing
Ian Laing Founder & Non-Executive Director @ Adaptimmune
Founder & Non-Executive Director
2008-12-01

helen-tayton-martin_image

Helen Tayton-Martin
Helen Tayton-Martin Chief Business Officer @ Adaptimmune
Chief Business Officer
2008-07-01

not_available_image

Adrian (Ad) Rawcliffe
Adrian (Ad) Rawcliffe Chief Executive Officer @ Adaptimmune
Chief Executive Officer

not_available_image

Dennis Williams
Dennis Williams TitleSr. Vice President, Late Stage Development @ Adaptimmune
TitleSr. Vice President, Late Stage Development
2019-12-01

not_available_image

John Lunger
John Lunger Chief Patient Supply Officer @ Adaptimmune
Chief Patient Supply Officer

james-noble_image

James Noble
James Noble Founder & CEO @ Adaptimmune
Founder & CEO
2008-07-01

not_available_image

Elliot Norry
Elliot Norry Senior Vice President & Chief Medical Officer @ Adaptimmune
Senior Vice President & Chief Medical Officer

Founder


ian-laing_image

Ian Laing

james-noble_image

James Noble

Stock Details


Company's stock symbol is NASDAQ:ADAP

Investors List

genentech_image

Genentech

Genentech investment in Post-IPO Equity - Adaptimmune

eight-roads-ventures_image

Eight Roads Ventures

Eight Roads Ventures investment in Venture Round - Adaptimmune

merlin-nexus_image

Merlin Nexus

Merlin Nexus investment in Series A - Adaptimmune

f-prime-capital-partners_image

F-Prime Capital

F-Prime Capital investment in Series A - Adaptimmune

wellington-management_image

Wellington Management

Wellington Management investment in Series A - Adaptimmune

ridgeback-capital_image

Ridgeback Capital

Ridgeback Capital investment in Series A - Adaptimmune

university-of-oxford_image

University of Oxford

University of Oxford investment in Series A - Adaptimmune

foresite-capital_image

Foresite Capital

Foresite Capital investment in Series A - Adaptimmune

novo-a-s_image

Novo Holdings

Novo Holdings investment in Series A - Adaptimmune

venbio_image

venBio Partners

venBio Partners investment in Series A - Adaptimmune

Official Site Inspections

http://www.adaptimmune.com Semrush global rank: 2.44 M Semrush visits lastest month: 7.35 K

  • Host name: ec2-174-129-30-187.compute-1.amazonaws.com
  • IP address: 174.129.30.187
  • Location: Ashburn United States
  • Latitude: 39.0481
  • Longitude: -77.4728
  • Metro Code: 511
  • Timezone: America/New_York
  • Postal: 20149

Loading ...

More informations about "Adaptimmune" on Search Engine